Nidroxyzone (Furadroxyl) is an antibacterial agent. It was used for the treatment of experimental trypanosomiasis in laboratory animals.

Bitoscanate is a tasteless, odorless, colorless, needle-like crystalline solid material prepared from mustard powder acid and used as an anthelmintic against nematodes, especially hookworms (Necator sp.) and Ancylostoma duodenale. Side effects reported with therapeutic use have been nausea, vomiting, diarrhea, abdominal pain or discomfort, loss of appetite, dizziness or giddiness, vertigo, weakness, headache, and an itching sensation over the body. Such side effects have most often been mild and required no treatment. Bitoscanate is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.

Naftoxate is an antimicotic agent. It is effective against both gram-positive and gram-negative bacteria as well as yeasts and other fungi in plant cell culture.

Cetefloxacin is an oral fluoroquinolone derivative with potent antibacterial activity against a broad spectrum of microorganisms being particularly active against gram-positive bacteria. Cetefloxacin is highly toxic and mortality was recorded among rats receiving 2000 or 1000 mg/kg/d. Rats receiving dosages of 450 or 2000/1000 mg/kg/d showed less activated mandibular lymph nodes, cortical lymphocyte depletion of mandibular and/or mesenteric lymph nodes, atrophy of the white pulp of the spleen, cortical atrophy of thymus and thymic apoptosis. Enlarged caeca, increased water consumption and variations in plasma electrolyte levels were observed in animals receiving these dosages and in male rats receiving 100 mg/kg/d. Low neutrophil counts were observed in rats receiving dosages of 100 or 450 mg/kg/d, and increased alkaline phosphatase and alanine transaminase plasma levels and slightly decreased plasma protein levels in females receiving 450 or 2000/1000 mg/kg/d. Marmosets receiving dosages of 50 mg/kg/d and above displayed several clinical signs which included emesis, diarrhoea, ptosis, occasional episodes of under- and overactivity, and excessive scratching activity. Skin reddening was observed during the first week of treatment in marmosets receiving 300 mg/kg/d.

Sulfaloxic acid is a benzamide derivative patented by Chemische Fabrik von Heyden A.-G. as an antibacterial agent.

Droxacin is quinolone antibiotic. It is topoisomerase inhibitor.

Troquidazole (EGIS-4136) is a radiosensitizer. It is a nitroquinoline derivative which enhances the radiosensitivity of hamster’s ovarian cells in both normoxia and hypoxia. Misonidazole at a concentration of 5 mM exerted a radiosensitizing effect as strong as 0.5 mM EGIS-4136.

Metipirox was developed as a bactericide agent. Information about the current use of this compound is not available

Vebufloxacin (OPC-7241) is a nalidixic acid analog. It exhibited potent antibacterial activity against gram-positive and -negative bacteria, including Staphylococcus aureus and Pseudomonas aeruginosa.

Amenamevir is an antiviral agent discovered by Astellas Pharma Inc. and is considered to exert anantiviral effect by inhibiting the activity of the helicase-primase complex, which is involved in DNA replication of herpes virus. It is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster virus. Amenamevir inhibited the in vitro replication of HSV-1 with a mean 50% effective concentration (EC(50)) of 14 ng/ml. Amenamevir was approved in Japan for the treatment of Herpes zoster.